LifeMD, Inc. (NASDAQ:LFMD) CMO Jessica Friedeman Sells 30,000 Shares of Stock

LifeMD, Inc. (NASDAQ:LFMDGet Free Report) CMO Jessica Friedeman sold 30,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.66, for a total value of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares of the company’s stock, valued at $962,200. This represents a 15.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

LifeMD Stock Performance

LFMD opened at $5.71 on Tuesday. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88. The firm has a market capitalization of $254.57 million, a PE ratio of -8.92 and a beta of 1.50. The business’s 50-day simple moving average is $5.68 and its 200 day simple moving average is $5.39.

LifeMD (NASDAQ:LFMDGet Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The business had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. On average, research analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on LFMD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research report on Tuesday, March 11th. B. Riley raised LifeMD to a “strong-buy” rating in a research report on Tuesday, March 11th. Lake Street Capital initiated coverage on LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. KeyCorp dropped their target price on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright upped their target price on LifeMD from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.43.

Read Our Latest Report on LifeMD

Institutional Trading of LifeMD

Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp raised its stake in LifeMD by 20.0% in the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after buying an additional 192,861 shares during the period. Royce & Associates LP raised its stake in LifeMD by 23.9% in the fourth quarter. Royce & Associates LP now owns 1,115,991 shares of the company’s stock valued at $5,524,000 after buying an additional 214,950 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in LifeMD by 21.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company’s stock valued at $4,610,000 after buying an additional 165,378 shares during the period. Millennium Management LLC raised its stake in LifeMD by 17.1% in the fourth quarter. Millennium Management LLC now owns 885,987 shares of the company’s stock valued at $4,386,000 after buying an additional 129,327 shares during the period. Finally, Geode Capital Management LLC raised its stake in LifeMD by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock valued at $4,071,000 after buying an additional 2,984 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

(Get Free Report)

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

See Also

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.